Skip to main content

Table 1 Patients characteristics

From: Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

Characteristics

 

Sex: Male/Female

17/14

Age (years)

 

   Median

60

   Range

24-81

WHO Performance status, n(%)

 

   0

10 (32)

   1

16 (52)

   2

4 (13)

   3

1 (3)

Primary tumor location, n (%)

 

   Colon

23

   Rectum

8

Metastatic sites, n (%)

 

   Liver

26 (84)

   Lung

13 (42)

   Peritoneum

5 (16)

   Others

12 (39)

Number of metastatic sites, n (%)

 

   1

15 (48)

   2

10 (32)

   ≥ 3

7 (23)

Chemotherapy associated with bevacizumab, n (%)

 

   FOLFIRI

19 (61)

   FOLFOX4

12 (39)

Line number of bevacizumab, n (%)

 

   2nd line

1(3.25)

   3rd line

10 (32.25)

   4th line

10 (32.25)

   5th or later-line

10 (32.25)

Previous chemotherapy

 

   Fluoropyrimidine + irinotecan + oxaliplatin

27

   Fluoropyrimidine + irinotecan

3

   Fluoropyrimidine + oxaliplatin

1

   Cetuximab

19